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Background: A major obstacle in treating colorectal cancer (CRC) is the acquired resistance to chemotherapeutic
agents. An important protein in the regulation of cancer cell death and clinical outcome is Raf kinase inhibitor
protein (RKIP). In contrast, activated signal transducer and activator of transcription 3 (STAT3) is a protein that
promotes tumor cell survival by inhibiting apoptosis and has an important role in cancer progression in many of
cancer types. The aim of this study was to evaluate the regulation of RKIP and STAT3 after treatment with clinically
relevant chemotherapeutic agents (camptothecin (CPT) and oxaliplatin (OXP)) and the cytokine interleukin-6 (IL-6) in
HCT116 colon cancer cells as well as evaluate the association between RKIP and STAT3 with clinical outcome of
Stage II colon cancer patients.
Methods: HCT-116 colon cancer cells were treated with CPT, OXP, and IL-6 separately or in combination in a time
and dose-dependent manner and examined for phosphorylated and non-phosphorylated RKIP and STAT3 via
Western blot analysis. STAT3 transcriptional activity was measured via a luciferase reporter assay in HCT116 cells
treated with CPT, IL-6 or transfected with JAK 1, 2 separately or in combination. We extended these observations
and determined STAT3 and RKIP/ pRKIP in tumor microarrays (TMA) in stage II colon cancer patients.
Results: We demonstrate IL-6-mediated activation of STAT3 occurs in conjunction with the phosphorylation of RKIP
in vitro in human colon cancer cells. OXP and CPT block IL-6 mediated STAT3 activation and RKIP phosphorylation
via the inhibition of the interaction of STAT3 with gp130. We determined that STAT3 and nuclear pRKIP are
significantly associated with poor patient prognosis in stage II colon cancer patients.
Conclusions: In the analysis of tumor samples from stage II colon cancer patients and the human colon carcinoma
cell line HCT116, pRKIP and STAT3, 2 proteins potentially involved in the resistance to conventional treatments were
detected. The phosphorylation of pRKIP and STAT3 are induced by the cytokine IL-6 and suppressed by the
chemotherapeutic drugs CPT and OXP. Therefore, these results suggest that STAT3 and pRKIP may serve as
prognostic biomarkers in stage II colon cancer patients and may improve chemotherapy.
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Globally, (CRC) is the third most common diagnosed
cancer in men and second in women {Jemal, 2011 #316}.
With the annual worldwide incidence rate of colon
cancer rising to over 1.2 million in 2008, up from less
than 0.95 million in 2005, the number of annual deaths
has also risen by 100,000 in the same three-year span
[1,2]. Surgical resection is the only curative treatment
option for local regional disease. Clinical outcome is
dependent upon extent of disease at presentation, also
known as tumor stage. Five-year survival rates according
to tumor stage at diagnosis based on the patient data
collected in the SEER database between 1991 and 2000
were as follows: 72-85% for stage II patients, 44-83% for
stage III patients, and 8% for stage IV [3]. For patients
that have undergone potentially curative resection
(stage II and III patients), disease recurrence has been
attributed to clinically occult micro-metastases present at
the time of surgery, which are targeted by postoperative
therapy. However, despite multi-modality therapy, survival
rates are still modest. As a result multiple hypotheses have
been developed to account for the limitations in current
treatment modalities. One argument described discusses
the impact of genetic aberrations that arise during the
development of CRC, which can lead to a reduced
susceptibility to apoptosis which could account for the
resistance to chemotherapy [3-5].
Raf kinase inhibitor protein (RKIP) is a member of the
phosphatidylethanolamine-binding protein family [6]
and is an inhibitor of the mitogen-activated protein kin-
ase cascade initiated by Raf-1 [7]. RKIP can affect vari-
ous diseases including cancer, Alzheimer’s disease, and
pancreatitis, which makes it a logical target for individu-
alized therapy and disease-specific interventions [8]. The
antagonizing effects of RKIP on cell survival also extends
to the NF-κB (Nuclear Factor kappa B) [9] and GRK2
(G Protein-Coupled Receptor Kinase 2) pathways [10].
RKIP is induced upon exposure to many chemotherapeutic
agents and plays a key role in the apoptosis of tumor cells
[11]. Studies have shown that when RKIP is phosphory-
lated on the Ser153 residue by PKC (Protein Kinase C)
it is inactivated and subsequently dissociates from Raf-1,
therefore ending the inhibition of the Raf-MEK-ERK
proliferation pathway [12,13].
STAT family proteins are localized primarily in the
cytoplasm, but upon activation (phosphorylation and
acetylation) they dimerize and localize to the nucleus to
regulate genes involved with cellular growth, proliferation
and metastasis [14-16]. STAT3 is phosphorylated on a
tyrosine residue (pY705) by Janus kinases (JAKs) [17,18].
Abnormal JAK activity is primarily responsible for the
constitutive activation of STAT3 and the development of a
tumorigenic phenotype in various cancers, including colon
[19-23]. Therefore, disrupting the activation of STAT3 hasthe potential to enhance chemotherapy induced apoptosis
and treatment outcomes.
Interleukin-6 (IL-6) is an inflammatory chemokine
released by a variety of cells, including T-cells and
macrophages, which binds and signals through the
IL-6 receptor and the β-receptor subunit glycoprotein
130 (gp130) [24-26]. IL-6 stimulation through gp130
activates the JAK/STAT pathway, leading to cell prolifera-
tion and survival [27,28]. IL-6 has been linked to metasta-
sis into bone [29,30] and elevated IL-6 levels have been
observed in various tumors and cell lines [31,32]. Thus,
aberrantly high IL-6 levels cause the phosphorylation of
STAT3 [19], leading to cancer cell survival [14,22]. In
colon cancer, the membrane bound IL-6 receptor expres-
sion was found to be decreased, whereas the production
of soluble IL-6 receptor was increased, leading to greater
STAT activation and the induction of pro-survival proteins
[33,34]. IL-6 signaling has been shown to be TGF-beta
dependent, where suppression of TGF-beta led to decreased
STAT activation and the prevention of in vivo tumor
progression [33].
Currently, patients with node positive or metastatic
colon cancer demonstrate an overall survival benefit
when treated with a fluoropyrimidine-based regimen.
Colon cancer patients with metastatic disease receiving
an OXP combination chemotherapy are about twice as
likely to respond to treatment compared to the same
drug combinations without OXP [35,36]. It has also been
demonstrated that these patients survive longer [36]. Over
the last decade, similar fluoropyrimidine combinations have
been evaluated in patients with node positive disease, and
unlike patients with metastatic colon cancer, improvement
in clinical outcome was only demonstrated in regimens of a
fluoropyrimidine alone or in combination with OXP,
also referred to as FOLFOX. [37,38]. Unfortunately,
the survival benefits of patients treated with a combination
of 5-fluorouacil leucovorin, and, the CPTanalog, irinotecan
(a combination known as FOLFIRI) is restricted to stage
IV colon cancer, [3] and the response rate in this patient
population is roughly about 50% [36,39]. The benefits of
FOLFOX post-operative systemic therapy has been clearly
demonstrated in stage III disease, the value in stage II is
small but present; and on subgroup analysis, patients with
high-risk stage II tumors demonstrated a trend toward
improved disease free survival. Current standard, supported
by the National Comprehensive Cancer Network (NCCN)
is FOLFOX and consists of 5-fluorouracil, leucovorin, and
oxaliplatin (OXP) [38,40].
OXP is a derivative of cisplatin that is able to cause
apoptosis in cells previously resistant to cisplatin [41].
Apoptotic signaling is initiated when OXP binds to DNA,
forming a DNA adduct [40]. Camptothecins (CPTs) are
another class of chemotherapeutic compounds used clin-
ically to treat various malignancies including metastatic
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topoisomerase 1 by binding to the DNA-Top1 complex
and preventing the replication of DNA [42]. Camptothecin
derivatives can induce RKIP expression and apoptosis in
some human cancer cells [11].
One major obstacle in elongating the post-treatment
survival of patients after conventional therapies, such as
radiation and chemotherapeutic drugs like OXP and CPT,
is the acquired resistance observed in many patients
with colon cancer [43-45]. One way to understand
the mechanism by which this resistance arises is to
analyze how the drug modulates proteins involved
with survival and apoptosis. Therefore, it is necessary
to find specific gene and protein targets to help improve
the outcome of colon cancer treatment. Recent reports
indicate that RKIP may serve as a potential biomarker in
Dukes’ B CRC patients and used to identify ‘high-risk’
patients with aggressive CRC and these patients should be
considered for adjuvant therapy, which may be dependent
on intratumoural heterogeneity [46,47].
In this study we demonstrate that IL-6 mediated activa-
tion of STAT3 occurs in conjunction with the phosphoryl-
ation of RKIP in vitro. OXP and CPT are able to block the
IL-6 mediated STAT3 activation and RKIP phosphorylation
via the inhibition of the interaction of STAT3 with gp130.
We extended these observations and determined that that
STAT3 and nuclear pRKIP are associated with poor patient
prognosis in stage II colon cancer patients.
Methods
Materials
The CPT derivative ST2614 was provided by Sigma Tau
Inc., Rome, Italy. Recombinant human IL-6 was purchased
from BD Pharmingen Biosciences. All other reagents and
chemicals were purchased from Sigma Chemical Co. un-
less otherwise noted. Protein quantification reagents were
obtained from Bio-Rad Laboratories Inc. and Thermo
Scientific. Enhanced chemiluminescence reagents and
secondary mouse and rabbit antibodies conjugated to
horseradish peroxidase for Western blot analysis
were from GE Healthcare. The antibodies to STAT3
(sc-482), pRKIP (sc-32623), gp130 (SC-655) and actin
(SC-1616) were purchased from Santa Cruz Biotechnology;
STAT3 pY705 (9131S) and PARP (9542S) from Cell
Signaling Technology; RKIP (07–137) and Histone 2AX
(07–67) from Millipore, Milford, MA.
Cells and plasmid
The human colon cancer cell lines, HCT116 and HT29
were purchased from ATCC (Rockville, MD). The HCT116
cells were grown in McCoy’s 5A and HT29 cells in
RPMI1640 medium (Invitrogen) supplemented with 10%
fetal bovine serum, glutamine, non-essential amino acids,
100 units/ml penicillin, and 100 μg/ml streptomycin. Theywere cultured in a humidified incubator at 37°C containing
5% CO2.
Western blot analysis
Total cell extracts were prepared as previously reported
[11] and the protein concentrations of lysates were
determined using either Bradford assay kit (BioRad)
or BCA protein assay kit (Pierce). Proteins were separated
by 10% SDS-PAGE and electrophoretically transferred from
the gel to nitrocellulose membranes (GE Healthcare). Pro-
teins recognized by antibodies were detected by enhanced
chemiluminescence (ECL) reagents (GE Healthcare).
Annexin V apoptosis analysis
HCT116 cells were plated at 3 X 105 and treated with
the appropriate agent for the indicated times. Cells were
harvested with 0.25% trypsin (Invitrogen) and the PE
Annexin V Apoptosis Kit 1 (BD Pharmingen) was used
according to the manufacturer’s protocol to measure
early and late stage apoptosis. Cells that stained positive
for both 7-AAD and PE Annexin V (7+ and PE+) are in
late stage apoptosis whereas those that stain PE+, but 7- are
still in the early stages of apoptosis. Staurosporine was used
as a positive control of apoptosis.
Transfection of HCT116 cells
Cells were transiently transfected using the Lipofectamine
transfection reagent (Invitrogen) according to the manu-
facturer’s protocol. Total DNA quantities of 1 or 2 μg
were transfected per sample.
STAT3 luciferase reporter assay
Cells (3 x 105 cells/60 mm dish) were transiently
transfected with 0.25 μg of a reporter plasmid containing
STAT3 binding fragments of the promoter region of
mouse IRF1 gene using lipofectamine in serum-free
medium [14]. After 3 hours, OPTI-MEM containing
FBS (fetal bovine serum) was added to the cells at a final
concentration of 20% FBS. Cells were harvested by
scraping, washed twice with PBS and lysed in passive
lysis buffer (Promega). The luciferase activity in the
cytosolic supernatant was evaluated using the Dual
Luciferase Reporter Assay (Promega) and measured using
a luminometer (Lumat LB 9507, Berthold Technologies)
to estimate transcriptional activity.
Immunoprecipitation assay
Cells were transfected with an empty vector (EV) or
indicated plasmids for 48 h. In experiments exploring
CPT, cells were treated at 200 nM for 16 h. Samples
were lysed in RIPA buffer with complete protease inhibitors
(Roche). Approximately 5% of the sample was removed
for total protein analysis of the immunoprecipitaion
(IP) input. The remainder of the sample, 1.5 mg of protein,
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on a rotator for 4 h at 4°C. Immunocomplexes were
isolated with protein G-agarose beads, separated by
10% SDS-PAGE, and electroblotted to a nitrocellulose
membrane. Proteins were detected via incubation with
the indicated antibodies and an ECL detection system.Patients and specimens
Archival cases of Stage II colorectal adenocarcinoma
from 140 consecutive patients were collected between
the years of 1986 to 2005 from the archives of the
Department of Pathology at the Rhode Island Hospital.
Stage was defined according to American Joint Committee
on Cancer criteria [48]. None of these patients received
adjuvant chemotherapy or radiotherapy before surgery or
after the initial resection. Recurrence and survival
data were ascertained through the Rhode Island Tumor
Registry and Rhode Island Hospital chart review. The
Institutional Review Board at the Rhode Island Hospital
approved this study. All tissue samples were formalin fixed
and paraffin embedded. The corresponding H&E slides
were reviewed for confirmation of diagnosis and adequacy
of material by SL and MR.Tissue microarray (TMA) construction
Paraffin blocks containing areas consisting of invasive colon
carcinoma were identified on corresponding H&E-stained
sections as previously described [49]. Areas of interest
that represented non-necrotic invasive front of the
adenocarcinoma were identified and marked on the
source block. The source block was cored, and a 1-mm
core was transferred to the recipient “master block” using
the Beecher Tissue Microarrayer (Beecher Instruments).
Three to six cores of tumor were arrayed per specimen. In
addition, a core of normal adjacent colonic mucosa was
also sampled when present.Immunohistochemistry
Immunohistochemistry for each antigen was done on
5-μm-thick paraffin sections of colon cancer tissue
microarray sample described above. The microarrays
were immunohistochemically stained for phosphorylated
RKIP and a full-length STAT3 antibody (polyclonal rabbit;
1:150; Santa Cruz Biotechnology, Inc.) using the Ventana
Discovery automated system using the DABMAP and
CC1 antigen retrieval (Ventana Medical Systems, Inc.).
Slides were dehydrated, cleared, and mounted. Positive
controls consisted of multitumor and normal tissue
microarrays generated in our department. Negative
controls included replacement of the primary anti-
body with non-reacting antibodies of the same
species.Quantitative immunohistochemical analysis
The nuclear and the cytoplasmic staining patterns were
separately quantified, for both phosphorylated RKIP and
STAT3, using a semiquantitative system for evaluation
and grading of the immunostaining pattern, successfully
applied by us and others [50,51]. The phosphorylated
RKIP (nuclear and cytoplasmic) staining intensity was
scored into four categories: 0 for complete absence of
the staining, 1 for weak staining, 2 for moderate, and 3
for strong staining. The extent of the positively stained
cells was also scored into a percentage. Each core
was given a score derived from the calculation of
grade −1 + percentage/100 (e.g. 1.5 is the final score
of a grade 2 with 50% positive area). Score of each
case is the average of all the cores of the case. At
least three cores were scored per case. The STAT3
staining intensity was scored in the same fashion. The
score ranges from 0 to 3. This scoring system takes
both intensity and extension into consideration. To
convert it into a more understandable quantile format,
scores of 0 are graded as 0, scores >0 and < =1 are graded
as 1+, scores >1 and < =2 are graded as 2+, and scores >2
are graded as 3+. All sections were scored independently
by SL and were blinded to the clinicopathologic features
or clinical outcome.
Statistical analysis
Chi-square analysis was used to evaluate the association
between STAT3 expression and tumor grade and
lymphovascular invasion (LVI) in tumor. All tests were
two-sided and p-values of 0.05 or less were considered
statistically significant. Statistical analyses were done using
the JMP 8.0 statistical program (SAS Institute, Cary, NC).
The vast majority of the cases have a complete set of
staining data and clinicopathologic information upon
which statistical analysis was performed. All cell culture
experiments were repeated at least 3 times, unless
indicated otherwise, and paired t-tests were used to
determine statistical significance.
Results
Treatment with IL-6 enhances phosphorylated RKIP levels
IL-6 has been shown to lead to STAT3 activation in
colon cancer [27,28]. HCT116 cells were treated for 1, 3
and 6 h with 40 ng/ml IL-6 and examined for STAT3
and RKIP phosphorylation. As expected, we observed an
increase in pY705STAT3 but were surprised to also
note an increase in pRKIP (Figure 1A). To our knowledge
this is the first report to show cytokine-mediated
phosphorylation of RKIP.
Oxaliplatin inhibits IL-6 signaling
Previous studies have shown that treating CRC CT26
cells with 300 μM OXP for 24 h leads to about 50% of
Figure 1 Oxaliplatin (OXP) reduces the phosphorylation of STAT3 and RKIP that is induced by interleukin-6 (IL-6). Western blot analysis
of: (A) the indicated proteins in HCT116 cells treated with IL-6 (40 ng/ml) for 1–6 h. (B) HCT116 cells treated with 300 μM OXP, IL-6 (40 ng/ml) in
serum free medium or the combination for 16 h and analyzed for the indicated proteins via Western blot analysis. (C) Cell extracts were prepared
after 18 h following treatment with OXP, IL-6 or the combination for flow cytometric analysis to examine binding to 7-AAD and annexin-V
(% Apoptosis). The % Apoptosis of each sample is indicated in the top right corner of every panel: a) untreated control cells (0.20%); b) 5 μM STS
(70.94%); 300 μM OXP (31.04%); d) IL-6 (4.01%); e) OXP + IL-6 (19.56%). STS is the positive control. The figure is representative of part of 1
experiment performed in duplicate. The experiment was repeated twice.
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treatment with OXP induced approximately 32% of the
cells to undergo apoptosis, which was lowered to 19% after
co-treatment with IL-6 (Figure 1C). Western blot analysis
showed that co-treatment of HCT116 cells with IL-6
and 300 μM OXP for 18 hours inhibited the increase
in pY705 STAT3 and pRKIP caused by IL-6 (Figure 1C).
OXP induced apoptosis was confirmed with Western blot
analysis by measuring PARP (Poly-ADP-ribose polymerase)
cleavage and DNA damage by H2AX (Histone 2AX)
phosphorylation [11,53,54] (Figure 1B).
CPT (ST2461) reduces IL-6 induced RKIP phosphorylation
and STAT3 transcription
Camptothecin is frontline therapy for metastatic CRC [3].
Therefore, we investigated if CPT could affect STAT3
phosphorylation. Western blot analysis revealed a dose-
dependent decrease of STAT3 pY705 phosphorylationwhen cells were treated with 40 ng/ml IL-6 in the
presence of 250–750 nM CPT for 12 h (Figure 2A).
The same experiment was repeated and the cells were
treated with 250 nM CPT and 40 ng/ml IL-6. We
observed a reduction of pRKIP when the cells were treated
with both compounds (Figure 2B). We measured apop-
tosis in the samples via Annexin staining from Figure 2B
and found that treatment with 250 nM CPT led to
approximately 17% of the cells to undergo apoptosis,
which was reduced to 7% after co-treatment with IL-6
(Figure 2C). STAT3 luciferase reporter assay confirmed a
significant decrease (p < 0.0002) in STAT3 transcription
when cells were treated with IL-6 and CPT (Figure 2D).
We found that these effects were also recapitulated in
HT29 colon cancer cells (Additional file 1: Figure S1). In
addition to inhibiting TOP I, this CPT analogs can also
interfere with cytokine-mediating signaling events that
lead to RKIP and STAT3 phosphorylation.
Figure 2 Camptothecin (CPT) reduces phosphorylation of STAT3 and RKIP induced by interleukin-6 (IL-6). (A) Western blot analysis of: a
dose-dependent reduction of STAT3 phosphorylation after IL-6 treatment then treated with 250–750 nM CPT; HCT116 cells treated with 250 nM
CPT and 40 ng/ml IL-6 for 12 h. (B) The same co-treatment experiment as in (A) was repeated with HCT116 cells treated with 250 nM CPT and
40 ng/ml IL-6 for 12 h. Western blot analysis was performed to examine the protein levels of pRKIP, RKIP and actin. (C) Cell extracts were
prepared after 18 h following treatment with CPT, IL-6 or the combination for flow cytometric analysis to examine binding to 7-AAD and
annexin-V (% Apoptosis). The % Apoptosis of each sample is indicated in the top right corner of every panel: a) untreated control cells (0.48%);
b) CPT (17.68%); c) IL-6 (0.64%); d) CPT + IL-6 (10.94%). The figure is representative of part of 1 experiment performed in duplicate. The experiment was
repeated twice. (D) HCT116 cells were transfected with an IRF-1 reporter plasmid for STAT3 activation. After 48 h, the cells were washed and treated
with 40 ng/ml IL-6, 250 nM CPT, or the combination. After 24 h, samples were harvested and washed twice before being lysed and combined with a
luciferase assay reporter. The data is reported as the mean +/− s.d. of 2 independent experiments performed in triplicate. A paired t-test was
performed to analyze the increase in STAT3 transcription of IL- 6 treated experimental samples when compared to vehicle (CTR): *IL-6, p < 0.000012; or
decrease when comparing IL-6 to samples treated with **IL-6 and CPT, p < 0.0002.
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IL-6 treatment enhances STAT3 phosphorylation, tran-
scription and pRKIP (Figures 1 and 2). We examined if
STAT3 overexpression could directly affect pRKIP and
Western blot analysis showed that the expression levels of
phosphorylated RKIP increased upon transfection with
STAT3 (Figure 3A). In the presence of CPT, the levels of
pRKIP were reduced after STAT3 overexpression
(Figure 3A) when compared to STAT3 alone (Figure 3A).
This indicates, similar to our IL-6 results (Figure 2) that
CPT interferes with the kinase activity mediated by
STAT3 that results in RKIP phosphorylation.JAK induced transcription of STAT3 is inhibited by CPT
In order to further examine the disruptive effects of CPT
on HCT116 cells proliferation signaling we performed
various luciferase assays to measure STAT3 transcription.
JAK proteins are known to enhance STAT3 transcription
[17,18], thus we measured the effect of CPT on JAK-
mediated STAT3 transcription. We found that STAT3
transcriptional activity is significantly increased in cells
transfected with JAK1 (p < 0.0005) and JAK2 (p < 0.0001)
(Figure 3B). However, the addition of CPT decreasedJAK1 (p < 0.0002) and JAK2 (p < 0.0003)-mediated STAT3
transcription (Figure 3B).CPT diminishes pRKIP levels through the inhibition of
STAT3 by interacting with GP130
To delineate the observed changes in pY705 STAT3 levels
after CPT treatment we performed an immunoprecipita-
tion assay. Western blot analysis revealed that the inter-
action between gp130 and STAT3 is IL-6 dependent and
that this interaction is interrupted by CPT treatment
(Figure 3C). This indicates that treatment with CPT
leads to the disruption of subsequent phosphorylation
events after IL-6 treatment. Collectively our results
(Figures 1, 2 and 3) suggest that CPT affects multiple
pathways leading to diminution of kinase activities.Clinicopathologic features of cancer patients luciferase
reporter assay luciferase reporter assay
To see if we could correlate our cell-based studies with the
colon cancer patient clinical outcome we examined a TMA
of 140 patients. The mean age of the patients at initial
surgery was 74.3 years (range, 30–97 years); 66 men and 74
women were included in the study. The mean duration of
Figure 3 Camptothecin blocks STAT3 activation and the interaction of STAT3 and the gp130 receptor. (A) Western blot analysis for the
indicated proteins from HCT116 cells transfected with STAT3 cDNA and then treated with 250 nM CPT for 16 h. (B) HCT116 cells were transfected
with an IRF-1 reporter plasmid to measure STAT3 activation along with JAK1 and 2 cDNAs. After 48 h, cells were washed and treated 250 nM
CPT. After 24 h, the samples were harvested and washed twice before being lysed and combined with a luciferase assay reporter. The data is
reported as the mean +/− s.d. of 2 independent experiments performed in triplicate. (C) HCT cells were transfected with STAT3 cDNA and gp130
cDNA. After 48 h, Samples were treated with 40 ng/ml IL-6 or IL-6 and 250 nM CPT. Samples were divided and either saved for Western blot
analysis (input) or incubated with an antibody to gp130 for 6 h. Protein G agarose beads were added and the samples rotated over night.
Western blot analysis was performed using the IP supernatant and examined for the indicated proteins. In comparison to empty vector controls
(EV), the relative activity of STAT3 transcription was increased by: *JAK1, p < 0.0005; **JAK2, p < 0.0001. In the presence of CPT, JAK1-mediated
STAT3 transcription was inhibited #JAK1 + CPT p < 0.0002 and JAK2 inhibited ## JAK2 + CPT p < 0.0003. The data represents the mean +/− s.d.
of 2 independent experiments performed in duplicate.
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tumors were Stage II with 25 cases of high grade and 115
cases of low grade based on the latest American Joint
Committee of Cancer tumor stage [48]. There were
13 tumors with LVI (lymphovascular invasion) and
127 tumors without LVI. The clinicopathologic features of
the patients are summarized in Table 1.
Expression of phosphorylated RKIP in colon cancer and
its prognostic value
The staining pattern for pRKIP is mixed, both cytoplasmic
and nuclear (Figure 4A). The cytoplasmic staining intensity
was graded 3+ in 66 cases (51.5%), 2+ in 46 cases (35.9%),
1+ in 14 cases (10.9%) and 0 in 2 cases. The nuclear stain-
ing intensity (Figure 4A) was graded 3+ in one case, 2+ in
26 cases (20.1%), 1+ in 84 cases (65.1%), and 0 in 18 cases
(14.0%). Kaplan Meier survival analysis of a limited number
of patients indicated a decrease in survival of patients with
elevated pRKIP (Figure 4B). The percent of patients with
low levels of pRKIP and no LVI was much greater than the
population with LVI (Figure 4C).Cytoplasmic and nuclear pRKIP have opposite associ-
ation with two important prognostic markers, tumor grade
and lymphovascular invasion (LVI). Twenty six percentage
(26%) cytoplasmic pRKIP-low (< 3+) tumors are high grade
compared with 11% cytoplasmic pRKIP-high (3+) tumors
being high grade (P = 0.024) (Table 2). Similarly 11% cyto-
plasmic pRKIP-low tumors have LVI while 6% cytoplasmic
pRKIP-high tumors have LVI (P = 0.29) (Table 2). Thus,
low expression of cytoplasmic pRKIP is associated with
high tumor grade and presence of LVI, i.e. worse prognosis.
In contrast, 19% of nuclear pRKIP-high (1-3+) tumors are
high grade as opposed to 11% of nuclear pRKIP-low (0)
tumors being high grade (P = 0.399) (Table 2). Similarly,
10% of nuclear pRKIP-high (1-3+) tumors have LVI while
0% of nuclear pRKIP-low tumors have LVI (P = 0.06)
(Table 2). In combination, the data suggests a shift of
pRKIP from cytoplasm to nuclei in the process of tumor
progression.
We examined the expression of RKIP in the same
cohort of patients and both cytoplasmic and nuclear
RKIP staining were evaluated by immunochemistry.
Table 1 The clinicopathologic features of the
patients studied






Mean (min, max) 74.3 (30–97)
Tumor size (mm)










Average follow-up time (mean, range)
76.6 months (16–250)
All patients were diagnosed with Stage II colorectal adenocarcinoma. Samples
were collected between the years of 1986 to 2005 from the archives of the
Department of Pathology at the Rhode Island Hospital.
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detected between RKIP expression level (high (2+ and 3+)
versus low (0 and 1+)) and tumor grade (p = 0.9191 for
cytoplasmic RKIP and p = 0.1918 for nuclear RKIP). Simi-
larly, no statistically significant associations were found
between RKIP expression level and LVI (p = 0.1779 for
cytoplasmic RKIP and p = 0.1897 for nuclear RKIP). In this
study, increased levels of RKIP was inversely associated
with tumor grade and high levels of nuclear RKIP was
associated with worse prognosis. These results suggest the
inactivation of RKIP function possibly via degradation [12],
mutation or other mechanisms in Stage II CRC.Expression of STAT3 in colon cancer and its association
with tumor grade and LVI
STAT3 expression in colon cancer is mainly nuclear
(Figure 5A). The nuclear staining intensity (Figure 5A)
was graded 3+ in 7 cases 5.5%), 2+ in 45 cases
(35.2%), 1+ in 56 cases (43.8%) and 0 in 20 cases (15.6%).
The impact of nuclear-STAT3 levels on tumor grade was
studied and a significantly greater percentage of nuclear-
STAT3 positive tumors are high grade (20%) compared to
nuclear STAT3 negative tumors (5%) (p = 0.064) (Table 2and Figure 5B). Five percent (5%) of nuclear STAT3-
negative tumors are high grade, however, 20% of nuclear
STAT3-positive (1-3+) tumors are high grade (P = 0.064)
(Figure 5B, Table 2). Therefore, nuclear-STAT3 levels are
associated with LVI. None of the nuclear STAT3-negative
tumors have any LVI while 10% of nuclear STAT3-positive
tumors have LVI (P-0.038) (Figure 5C, Table 2). Our results
indicate that nuclear STAT3 expression may be associated
with worse prognosis. Additional analysis of an increased
cohort of patients will be required to definitively determine
this. Our results indicate that an increased level of cytosolic
pSTAT3 is associated with higher tumor grade (p = 0.03)
(Figure 5D, Table 2).
Discussion
Recent studies show that RKIP levels are an important
predictor of tumor progression by measuring RKIP
levels at the tumor-front and in tumor budding [55,56].
Phosphorylated RKIP has been shown to be required to
promote gastric cancer progression after infection with
Helicobacter pylori [13]. However, few studies have
investigated the role of phosphorylated RKIP and its
ability to predict patient outcome. Huerta-Yepez et al.
found a significant correlation between pRKIP levels and
non-small cell lung cancer patient survival. This was the
first study to focus on the clinical significance of pRKIP,
revealing that normal levels of pRKIP are associated with
better prognosis than low levels [51]. In contrast, our
current study indicates that reduced pRKIP may be
associated with enhanced survival of stage II colon
cancer patients. There may be several reasons for the
discrepancies between the studies including that the
studies were performed on different tissue types. The phos-
phorylation of pRKIP may lead to the activation of distinct
pathways (i.e., cell survival, apoptosis, anoikis, etc.) in the 2
models, resulting in either better or worse patient progno-
sis. Here we show the inhibition of pRKIP by CPT and
OXP, 2 frontline chemotherapeutic agents used for the
treatment of colon cancer patients (Figures 1 and 2), had
the opposite correlation between pRKIP levels and patient
outcome in Stage II colon cancer. Stage II colon cancer
patients with low levels of nuclear pRKIP experienced
longer recurrence-free survival compared to that of
patients with high levels (Figure 4).
The interaction between RKIP and Raf-1 has been
shown to play an important role in CRC survival by
suppressing metastasis through the down-regulation
of Raf-1 [57] and the up-regulation of RKIP [58]. Fur-
thermore, when RKIP expression in CRC is down-
regulated in the cytoplasm, increased vascular invasion and
poor patient prognosis are observed [58]. Significantly,
RKIP, peritoneal invasion and LVI provide independent
prognostic information in Dukes’ B CRC patients [46]. As
previously shown, increased expression of RKIP in breast
Figure 4 Phosphorylated RKIP in stage II colon cancer is associated with poor prognosis. (A) Representative examples of
immunohistochemical staining for pRKIP showing strongly positive (3+) and negative levels. (B) Kaplan-Meier plot comparing the recurrence-free
survival of patients with high versus low levels of nuclear pRKIP. Patients with lower levels experienced significantly longer recurrence-free survival
(p = 0.0268). Bar is 100 micron. (C) Graphic representation of the correlation between lymphovascular invasion and pRKIP levels (p = 0.03).
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chemotherapeutic agent as measured by CPT induced
apoptosis [11], a similar mechanism may explain the role
of RKIP in the resistance to chemotherapeutic agents in
CRC patients. Another mechanism of therapeuticTable 2 Contingency analysis of cytoplasmic phosphorylated
and nuclear STAT3 (n-STAT3) expression and tumor Grade an
Marker Grade p-val
Low High
c-pRKIP n (%) n (%) 0.024
0, 1+, 2+ 46 (74%) 16 (26%)
3+ 59 (89%) 7 (11%)
n-pRKIP n (%) n (%) 0.399
0 16 (89%) 2 (11%)
1+, 2+, 3+ 90 (81%) 21 (19%)
n-STAT3 n (%) n (%) 0.064
0 19 (95%) 1 (5%)
1+, 2+, 3+ 86 (80%) 22 (20%)
The numbers and the percentages of cases are provided.resistance relating RKIP to the KEAP1/NRF2 pathway
has been described [59]. Apoptosis was associated with
the RKIP/KEAP1 expression levels in colorectal cancer
tissues, providing another mechanism by which diminution




n (%) n (%) 0.29
55 (89%) 7 (11%)
62 (94%) 4 (6%)
n (%) n (%) 0.06
18 (100%) 0 (0%)
100 (90%) 11 (10%)
n (%) n (%) 0.038
20 (100%) 0 (0%)
96 (89%) 12 (11%)
Figure 5 Nuclear STAT3 in stage II colon cancer is associated with negative pathological features. (A) Representative examples of
immunohistochemical staining for STAT3 showing strongly positive (3+) and negative levels. Bar is 100 micron. (B) Nuclear STAT3 is associated
with higher grade tumors, where fewer than 5% of high grade tumors received a negative staining score compared to nearly 22% of low grade
tumors (p < 0.0266). (C) Nuclear STAT3 is associated with lymphovascular invasion. No patients with LVI had negative nuclear STAT3 staining
(p < 0.0218). (D) High levels of cytoplasmic STAT3 are associated with tumor grade, with higher levels correlating with higher grade (p = 0.03).
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is responsible for the direct phosphorylation of RKIP
[12], our study has demonstrated that cell survival
signaling caused by IL-6 leads to phosphorylation of
RKIP (Figure 1). Since high IL-6 levels are linked to
tumor growth and progression in colon cancer [33,60]
it is logical that we also observed increased levels of
pRKIP in these patients. The association between IL-6,
pRKIP, and patient survival illustrates the necessity for
delineating the mechanism to inhibit the phosphorylation.
Previously, IL-6 has been shown to activate STAT3 in colon
cancer through phosphorylation on the tyrosine 705 residue
[27,28]. Our results suggest that IL-6 triggered STAT3 phos-
phorylation and activation is correlated with the increase in
pRKIP and thus the stimulation of the Raf/MEK/ERK survival
pathway. Whether IL-6 stimulation leads to the activation ofPKC or other kinase pathways leading to RKIP phosphoryl-
ation directly or if this event is associated with the phosphoryl-
ation of STAT3 is currently under investigation.
Based on our IHC observations, we further investigated
the phosphorylation levels of STAT3. IHC analysis revealed
that lower levels of nuclear STAT3 are associated with less
invasive tumors and the nuclear expression of STAT3 is
significantly associated with high-grade tumors and
the presence of lymphovascular invasion (Figure 5).
Recent studies have demonstrated details about the STAT3
nuclear localization mechanism [61] and have blocked this
localization in human multiple myeloma cells [23]. There-
fore, blocking STAT3 localization via Crm A, for example,
may be an effective approach to inhibit aberrant STAT3
activity resulting in the inhibition of the phosphorylation,
dimerization, or nuclear membrane transport mechanism
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disruption of the cell survival signals in colon cancer.
Chemotherapeutic regimens utilized clinically for patients
with stage III CRC typically include a fluoropyrimidine and
OXP, whereas a fluoropyrimidine backbone with OXP or
CPT is given to patients with stage IV disease. Our data
demonstrated that cell survival signaling triggered by IL-6
in HCT116 cells is mitigated by OXP and CPT. Western
blot analysis of HCT116 cells treated with IL-6 and OXP
demonstrated a reduction in both pRKIP and pY705STAT3
back to basal levels (Figure 1). The same observations were
made using IL-6 combined with CPT (Figure 2). Since the
HCT116 cells are not representative of a particular stage of
colon cancer, the fact that both OXP and CPT caused
similar reductions in phosphorylation suggests that
they trigger similar cellular mechanisms while causing
apoptosis. These results support an alternative anti-tumor
activity mechanism of action for these compounds.
Our data uncovered another mechanism by which an
irinotecan analog CPT (ST2461) is able to inhibit IL-6-
mediated STAT3 phosphorylation. STAT3 cannot bind to
the gp130 subunit of the IL-6 receptor until IL-6 binds to
the extracellular side of the receptor (Figure 3). Treatment
with CPT disrupted the binding if STAT3 to gp130 in the
presence of IL-6. This inhibition of binding explains why
STAT3 was no longer phosphorylated upon IL-6 stimula-
tion in the presence of CPT.
In order to further investigate the involvement of the
JAK/STAT pathway in enhancing colon cancer cell
survival and the mechanism of RKIP phosphorylation,
we examined whether JAK 1 and 2 overexpression could
stimulate STAT3 activation and thereby negate the
inhibitory effects of CPT. JAK 1 and 2 caused an increase
in STAT3 transcription, which was associated with an
increase in pRKIP. Treatment with CPT was able to
significantly reduce the levels of STAT3 transcription
activity and the levels of pRKIP (Figure 3). Therefore,
the versatility of camptothecin as a front line chemotherapy
agent is increased because, in addition to inhibiting
topoisomerase I, CPT is able to enhance apoptosis of
cancer cells by disrupting survival signaling of the
JAK/STAT pathway at the receptor level.
Conclusions
In summary, this study examines for the first time, the
expression profile of RKIP, pRKIP and STAT3 in Stage II
colon cancer. Our results strongly suggest the role of
pRKIP and STAT3 in the provision of clinically prognostic
and therapeutic information. Our data indicate that the
current treatment for colon cancer, FOLFOX and FOLFIRI,
are both effective in reducing pRKIP levels in vitro. There-
fore, examining a larger cohort of patients, in the future,
will provide additional data for the assessment of pRKIP
and STAT3 for the risk for recurrence of colon cancer.Consent
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